Abstract
Using structure-based drug design principles, we identified opportunities to reduce the lipophilicity of our tertiary sulfonamide RORc inverse agonists. The new analogs possessed improved RORc cellular potencies with >77-fold selectivity for RORc over other nuclear receptors in our cell assay suite. The reduction in lipophilicity also led to an increased plasma-protein unbound fraction and improvements in cellular permeability and aqueous solubility.
Keywords:
IL-17; Permeability; RORc; RORγ; Solubility; X-ray structure.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Binding Sites / drug effects
-
Blood Proteins / chemistry*
-
Blood Proteins / metabolism
-
Cell Membrane Permeability / drug effects*
-
Crystallography, X-Ray
-
Dogs
-
Dose-Response Relationship, Drug
-
Drug Design
-
Humans
-
Hydrophobic and Hydrophilic Interactions
-
Madin Darby Canine Kidney Cells
-
Models, Molecular
-
Molecular Structure
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / agonists*
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism
-
Rats
-
Solubility
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology*
Substances
-
Blood Proteins
-
Nuclear Receptor Subfamily 1, Group F, Member 3
-
RORC protein, human
-
Sulfonamides